Posted: Sep 21, 2010

MagForce Nanotechnologies AG Announces Publication of Clinical Data Using Nanoparticles for the Treatment of Recurrent Glioblastoma Multiforme

(Nanowerk News) MagForce Nanotechnologies AG announced today the publication of clinical data from a clinical study examining the safety and efficacy of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy in patients with recurrent glioblastoma multiforme.
The study data, published on September 20, 2010 in the Journal of Neuro-Oncology, is available online on the Journal's website at or
"This data publication provides detailed insight into the clinical data that supported our recent regulatory approval for Nano-Cancer® therapy. Through the publication, we are pleased to address a wider international audience and give them insight into MagForce's novel concept of using nanotechnology for the treatment of cancer," said Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG. "We are currently focused on strengthening our commercialization team and infrastructures in preparation for the next strategic steps, including the planned Q1 2011 product launch in Germany, additional clinical trials, and further internationalization."
Nano-Cancer® therapy uses iron oxide nanoparticles, which are injected into the tumor and, due to their special coating, aggregate and remain in place. The patient is then placed into a magnetic field applicator. Through the application of an alternating magnetic field, the nanoparticles begin to oscillate, produce warmth, and damage or kill the tumor tissue.
About MagForce Nanotechnologies
MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm and NanoActivator, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.
Source: MagForce Nanotechnologies
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: